Melissa Epperly - 23 Jun 2025 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Director
Signature
/s/ Mathew B. Murphy, as Attorney-in-Fact
Issuer symbol
NAUT
Transactions as of
23 Jun 2025
Transactions value $
$0
Form type
4
Filing time
25 Jun 2025, 16:37:40 UTC
Previous filing
21 Apr 2025
Next filing
21 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Epperly Melissa B, Director C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVE. E., SEATTLE /s/ Mathew B. Murphy, as Attorney-in-Fact 24 Jun 2025 0001807359

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAUT Stock Option (Right to Buy) Award $0 +45,000 $0 45,000 23 Jun 2025 Common Stock 45,000 $0.6951 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).